Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia

We describe recent updates of existing molecular-targeting agents and emerging novel gene-specific strategies. FLT3 and IDH inhibitors are being tested in combination with conventional chemotherapy for both medically fit patients and patients who are ineligible for intensive therapy. FLT3 inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Chi, Sung-Gi, Minami, Yosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879537/
https://www.ncbi.nlm.nih.gov/pubmed/35216478
http://dx.doi.org/10.3390/ijms23042362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879537/
https://www.ncbi.nlm.nih.gov/pubmed/35216478
http://dx.doi.org/10.3390/ijms23042362

Ejemplares similares